Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy